Skip to main content


We have shown that the SUR1/TRPM4 channel is upregulated in rodent models of ischemic stroke, and that we can significantly attenuate injury with administration of glibenclamide at non-hypoglycemic doses. Importantly, an archival study found that patients with type-2 diabetes who had a sulfonylurea on-board at the time of stroke had substantially improved outcomes over patients that were not taking a sulfonylurea.

We have recently completed the first of several studies aimed at characterizing the window of efficacy for glibenclamide administration.

Supported by the discoveries from this laboratory, the use of glibenclamide for the treatment of ischemic stroke is currently in a Phase II clinical trial (GAMES-PILOT).

Relevant publications


Click on images for larger versions.